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CASE REPORT
The patient was a 43-year-old male who had been 
diagnosed with Alport syndrome and dialytic chronic kidney 
disease in 1998. In November 2006, he was admitted to the 
hospital due to septic shock secondary to a hemodialysis 
catheter infection that developed into a femoral prosthesis 
infection. 
One month later, the patient underwent two MRI scans 
as preparation for the surgical prosthesis substitution. 
A gadolinium-based contrast agent was used with a 
gadodiamide dose of 0.15 mmol/kg in each exam, with a 
one-week interval between exams.
Two months after the MRI, the patient had thickening 
and hardening of the skin of the right forearm (Figure 1) that 
extended to the remaining limbs, as well as to a band lesion 
in the left lower limb (Figure 2). The remaining physical 
examination was normal. 
The laboratory findings included an increase in 
C-reactive protein to 52 mg/L, with a slight increase in 
serum ferritin to 320 ng/mL. Other tests were normal, such 
as the hemosedimentation velocity and serum albumin 
concentration. 
The pulmonary function test and the echocardiogram 
were both normal. A computed tomography (CT) scan of the 
affected areas showed diffuse thickening of the muscle, skin 
and subcutaneous tissue. The patient then underwent muscle 
and skin biopsies. 
Nephrogenic systemic fibrosis (NSF) was confirmed in 
the skin and muscle biopsies. Immunohistochemical analysis 
showed the presence of CD34+, CD68+ and factor XIIIa+ 
Figure 1 - Thickening and hardening of the skin of the right forearm 
Figure 2 - Band lesion in the left lower limb 
mono- and multinucleated cells, and electron microscopy 
showed gadolinium deposition in the muscle and skin.
Treatment with thalidomide and sodium thiosulphate was 
started, but no significant improvement has been observed.483
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DISCUSSION
NSF is a devastating and irreversible disease that affects 
the skin and other tissues in patients with impaired kidney 
function (especially in patients with creatinine clearance < 
30 ml/min).1,2 This report describes the first case of NSF in 
Brazil to the best of our knowledge. 
In NSF, the mean time between exposure to gadolinium 
and the onset of the lesions is 25 days, ranging from 2 to 75 
days.1
The characteristic clinical findings are lesions of the 
extremities, especially the hands and feet, as well as the 
absence of head and trunk lesions. The affected areas 
can initially present local edema and develop hard and 
erythematous plaques, resulting in dermal and epidermal 
fibrosis, or even fibrosis of deeper tissues such as muscles 
and internal organs.2
There are no specific laboratory findings associated with 
NSF. To attain a definite diagnosis, it is necessary to perform 
a biopsy of the affected area, to observe evidence of fibrosis 
in the form of markers such as CD34 and CD68, and to note 
gadolinium deposits in the affected area.1-3 
The differential diagnoses include dermatological 
pathologies  that  lead  to  skin  thickening  such  as 
scleromyxedema, scleroderma, eosinophilic fasciitis and 
calciphylaxis.3 
Several treatments for NSF have been tested, including 
both systemic treatments such as corticoids, sodium 
thiosulfate, cyclophosphamide and thalidomide, and topical 
treatments such as phototherapy. However, none of these 
agents have yet been shown to be definitively effective in 
reversing or even decreasing the progress of the disease.4
In individuals with normal kidney function, gadolinium 
rapidly distributes between the plasma and the interstitium. 
It has a half-life of 2 hours and is eliminated through 
glomerular filtration without any contribution from tubular 
secretion, with clearance varying from 1.1 to 1.6 ml/kg/
min. More than 95% of the injected dose is eliminated in 24 
hours, and less than 3% is eliminated in the stool.5 
In patients with advanced kidney failure (stage 5), the 
pharmacokinetics of the gadolinium complexes are altered. 
Due to their relatively low molecular weight (500 kDa), 
small volume of distribution (0.28 l/kg) and low protein 
binding, they are easily removed by hemodialysis, but not 
by peritoneal dialysis.5
 A study showed that the half-life of gadolinium in 
a patient with chronic kidney disease was 34.3 hours. It 
decreased to 2.6 hours in patients undergoing hemodialysis, 
whereas in the patients undergoing peritoneal dialysis, it 
increased to 52.7 hours.6
The existing data in the literature allow for the following 
recommendations for preventing and minimizing the risks of 
acquiring this disease; however, there is no treatment for this 
pathology at the present date.4,7 
The first and best measure is to suggest that all patients 
undergoing MRI should be evaluated for the presence of 
kidney disease, thus identifying those at increased risk 
of developing NSF, such as: patients with acute kidney 
disease, mainly associated with liver failure; patients 
that received kidney or liver transplants and have kidney 
disease; patients with kidney disease in stages 4 or 5 not 
undergoing dialytic therapy;5,10 and patients undergoing 
hemodialysis or peritoneal dialysis. Kidney function 
assessment is recommended for patients with elevated 
serum creatinine levels to ensure safety when performing 
the MRI. When a patient at risk of developing NSF is 
identified, the use of gadolinium should be avoided, unless 
such an examination is mandatory.5,8-10 If the MRI with 
gadolinium is truly essential, the lowest possible dose 
should be used,1,8-11 and multiple exposures to gadolinium 
should be avoided. The patient must be informed of the 
risks, benefits and alternatives. All at-risk patients that 
are exposed to examinations with contrast must undergo a 
clinical assessment. The use of gadolinium must be avoided 
in patients with acute kidney failure until the kidney 
function has recovered.8,9
Among patients with chronic kidney disease undergoing 
hemodialysis that are exposed to gadolinium, three 
hemodialysis sessions should be performed, with the first 
beginning within three hours after the exposure. It must be 
emphasized that the efficacy of hemodialysis in preventing 
NSF is unknown.8
For patients with chronic kidney disease undergoing 
peritoneal dialysis that are exposed to gadolinium, the 
number of dialysis bag changes should be increased, or the 
automatic peritoneal dialysis prescription should be extended 
to at least 48 hours. Also, hemodialysis should be considered 
for those that have vascular access and have been exposed to 
high or multiple doses of gadolinium, or if the nephrologist 
deems it necessary.8 
 Among patients with acute kidney disease or chronic 
kidney disease in stages 4 or 5 that are not undergoing 
dialysis and were exposed to gadolinium, it is not currently 
possible to estimate the risk of developing NSF. The 
decision to submit patients to dialysis must be assessed on 
an individual basis, by evaluating the risks and benefits in a 
joint decision among the nephrologist, the patient and the 
clinician.8
In conclusion, NSF is a progressive and potentially fatal 
disease that has been described in patients with acute or 
chronic kidney disease with a glomerular filtration rate < 30 
mL/min/1.73 m2 who are not undergoing dialysis therapy 484
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and are exposed to gadolinium-based contrast agents. To 
date, no therapy or combination of therapies has shown any 
consistent benefit for recovery of kidney function in NSF 
patients.
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